医学文献 >>
  • 检索发现
  • 增强检索
知识库 >>
  • 临床诊疗知识库
  • 中医药知识库
评价分析 >>
  • 机构
  • 作者
默认
×
热搜词:
换一批
论文 期刊
取消
高级检索

检索历史 清除

Carrier-free reduction-responsive self-assembling paclitaxel dimer nanoprodrug synergizing with celastrol for enhanced chemoimmunotherapy

摘要Chemotherapeutic paclitaxel(PTX)formulations are widely used in clinical cancer treatment;however,they are also associated with concomitant programmed death-ligand(PD-L1)upregulation and an immunosuppressive microenvironment.Herein,we rationally designed carrier-free,reduction-sensitive PTX dimer self-assembling nanoprodrugs(diPC NPs),composed of a glutathione(GSH)-responsive PTX dimer prodrug(diPTX)and the PD-L1 downregulator celastrol(Cel)for combinational chemoimmunotherapy.Following intravenous administration,the diPC NPs exhibited prolonged blood circulation and preferential tumor accumulation by exploiting the enhanced permeability and retention effect.Subsequently,the elevated GSH levels in tumor cells cleaved the disulfide bonds,triggering the rapid release of PTX and Cel.The released PTX elicited potent cytotoxic effects and induced immunogenic cell death(ICD),whereas the released Cel synergistically enhanced ICD and downregulated PD-L1 expression in tumor cells.Together,these effects resulted in remarkable antitumor efficacy with exhibited a favorable safety profile within the therapeutic window in both Lewis lung carcinoma cells and B16F10 tumor-bearing mice.Our findings highlight a promising strategy for highly efficient combination chemoimmunotherapy.

更多
广告
栏目名称
DOI 10.1016/j.ajps.2026.101124
发布时间 2026-04-09(万方平台首次上网日期,不代表论文的发表时间)
提交
  • 浏览1
  • 下载0
亚洲药物制剂科学(英文版)

加载中!

相似文献

  • 中文期刊
  • 外文期刊
  • 学位论文
  • 会议论文

加载中!

加载中!

加载中!

加载中!

法律状态公告日 法律状态 法律状态信息

特别提示:本网站仅提供医学学术资源服务,不销售任何药品和器械,有关药品和器械的销售信息,请查阅其他网站。

  • 客服热线:4000-115-888 转3 (周一至周五:8:00至17:00)

  • |
  • 客服邮箱:yiyao@wanfangdata.com.cn

  • 违法和不良信息举报电话:4000-115-888,举报邮箱:problem@wanfangdata.com.cn,举报专区

官方微信
万方医学小程序
new医文AI 翻译 充值 订阅 收藏 移动端

官方微信

万方医学小程序

使用
帮助
Alternate Text
调查问卷